RSS   Newsletter   Contact   Advertise with us
Post Online Media

Valeant appoints William Humphries as EVP, dermatology

Valeant PharmaceuticalsValeant Pharmaceuticals International announced that William D. Humphries has been appointed executive vice president, dermatology, effective January 2, 2017.
Article continues below

READ MORE Vodafone names Brian Humphries as group enterprise director

Mr. Humphries will join Valeant's Executive Committee. Mr. Humphries has nearly 30 years of experience in the dermatology and specialty pharmaceuticals industry.

He joins Valeant from Merz GmbH & Co. KGaA, where he most recently served as CEO of its North America business.

Prior to Merz, he served as President of Stiefel, a global dermatological pharmaceutical company, that is now a subsidiary of GlaxoSmithKline, and held multiple senior roles at Allergan, Inc., including Vice President of the U.S. skincare business.

Rob Rosiello will also depart the Company on December 31, 2016.

Mr. Rosiello previously served as the Valeant CFO from July 2015 through August 2016 and has successfully transitioned the role to the new CFO, Paul Herendeen.

Dr. Ari Kellen, EVP & Company Group Chairman will also depart Valeant on December 31, 2016.

Dr. Kellen and Mr. Rosiello will continue to serve as consultants on an ongoing basis.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy